Coronavirus Therapy / Cocrystal Pharma - LARVOL DELTA

Cocrystal Pharma announces plans to advance coronavirus program - "Cocrystal Pharma...today announced it has initiated its Coronavirus program....'Following our acquisition of patent rights and know-how from KSURF and our recently completed financing, we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform. Given the global threat of COVID1-9, our primary goal is to advance our Coronavirus program into preclinical development. We will seek opportunities for collaborations as we advance our programs'."

Licensing / partnership • New molecule • Preclinical

Cocrystal Pharma Announces Plans to Advance Coronavirus Program (GlobeNewswire, Cocrystal Pharma, Inc.) - "Company has immediately initiated Coronavirus program. Leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) ."

Commercial • Preclinical

Cocrystal Pharma reports 2019 financial results and outlines expected value-driving milestones for 2020 (GlobeNewswire, Cocrystal Pharma, Inc.) - "Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”)....Q2 2020: File patent application....Q2/Q3 2020: Develop COVID-19 inhibitors using proprietary platform technology....H2 2020: Initiate preclinical studies of COVID-19 inhibitors."

New molecule • Patent • Preclinical